Molecular and cellular basis of scleroderma

Journal of Molecular Medicine

Volumn 92, Issue 9, 2014, Pages 913-924

  Eckes, Beate ^a   Moinzadeh, Pia ^a   Sengle, Gerhard ^a   Hunzelmann, Nico ^a   Krieg, Thomas ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Extracellular microenvironment; Pathophysiology; Scleroderma; Signaling; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; FIBRILLIN;

AUTOIMMUNE DISEASE; BLOOD VESSEL INJURY; CELL ACTIVITY; CELL FUNCTION; CELL STRUCTURE; DERMATITIS; DIAGNOSTIC VALUE; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; FIBROBLAST; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; INFLAMMATION; MESENCHYME CELL; MICROENVIRONMENT; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; COMPLICATION; FIBROSIS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN; VASCULARIZATION;

ANIMALS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN;

EID: 84906320633     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1190-x     Document Type: Review

References (128)

1. Varga J (2012) Scleroderma - from pathogenesis to comprehensive management. Springer, New York
2. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989-2003
3. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737-2747
4. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Muller-Ladner U, Pfeiffer C, Riemekasten G et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 47:1185-1192 (Pubitemid 352038224)
5. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246-2255 (Pubitemid 36959206)
6. Allanore Y, Dieude P, Boileau C (2010) Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology (Oxford) 49:203-210
7. Feghali-Bostwick C, Medsger TA Jr, Wright TM (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48:1956-1963 (Pubitemid 36828691)
8. Reveille JD (2003) Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep 5:160-167
9. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44:1359-1362 (Pubitemid 32537534)
10. Agarwal SK, Tan FK, Arnett FC (2008) Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 34: 17-40; v. DOI 10.1016/j.rdc.2007.10.001
11. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, Milewicz DM, Chakraborty R, Arnett FC (2003) Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 48:2585-2592 (Pubitemid 37129435)
12. Allanore Y, Saad M, Dieude P, Avouac J, Distler JH, Amouyel P, Matucci-Cerinic M, Riemekasten G, Airo P, Melchers I et al (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7:e1002091
13. Dieude P, Guedj M, Wipff J, Avouac J, Fajardy I, Diot E, Granel B, Sibilia J, Cabane J, Mouthon L et al (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 60:225-233
14. Rueda B, Gourh P, Broen J, Agarwal SK, Simeon C, Ortego-Centeno N, Vonk MC, Coenen M, Riemekasten G, Hunzelmann N et al (2010) BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 69:700-705
15. Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, Coenen MJ, Vonk MC, Voskuyl AE, Schuerwegh AJ et al (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42:426-429
16. Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, Assassi S, Ying J, Tan FK, Arnett FC et al (2014) Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 94:47-61
17. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, Arnett FC (2001) Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44:893-901 (Pubitemid 32319782)
18. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N et al (2007) A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357:1210-1220 (Pubitemid 47443180)
19. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694-702 (Pubitemid 43985337)
20. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56:1010-1020 (Pubitemid 46399451)
21. Christmann RB, Sampaio-Barros P, Stifano G, Borges CL, de Carvalho CR, Kairalla R, Parra ER, Spira A, Simms R, Capellozzi VL et al (2014) Association of Interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol 66:714-725
22. Galluccio F, Walker UA, Nihtyanova S, Moinzadeh P, Hunzelmann N, Krieg T, Steen V, Baron M, Sampaio-Barros P, Kayser C et al (2011) Registries in systemic sclerosis: a worldwide experience. Rheumatology (Oxford) 50:60-68
23. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433-443
24. Nietert PJ, Silver RM(2000) Systemic sclerosis: environmental and occupational risk factors. Curr Opin Rheumatol 12:520-526
25. Namboodiri AM, Rocca KM, Pandey JP (2004) IgG antibodies to human cytomegalovirus late protein UL94 in patients with systemic sclerosis. Autoimmunity 37:241-244 (Pubitemid 39162682)
26. Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Beri R, Corrocher R, Puccetti A (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3:e2
27. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, BianchiDW(1998) Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559-562 (Pubitemid 28077562)
28. Artlett CM, Smith JB, Jimenez SA (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338:1186-1191 (Pubitemid 28180747)
29. Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161-170 (Pubitemid 11160329)
30. Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65:1953-1962
31. Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155-160 (Pubitemid 30058643)
32. Fleischmajer R, Perlish JS, West WP (1977) Ultrastructure of cutaneous cellular infiltrates in scleroderma. Arch Dermatol 113:1661-1666 (Pubitemid 8241731)
33. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, Molitor JA, Henstorf G, Lafyatis R, Pritchard DK, Adams LD, Furst DE, Schwartz SM (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3:e1452. DOI 10.1371/journal.pone.0001452
34. Kahaleh MB, Sherer GK, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326-1335 (Pubitemid 9209543)
35. Riemekasten G, Philippe A, Nather M, Slowinski T, Muller DN, Heidecke H, Matucci-Cerinic M, Czirjak L, Lukitsch I, Becker M et al (2011) Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 70:530-536
36. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255-263
37. Antsiferova M, Martin C, Huber M, Feyerabend TB, Forster A, Hartmann K, Rodewald HR, Hohl D, Werner S (2013) Mast cells are dispensable for normal and activin-promoted wound healing and skin carcinogenesis. J Immunol 191:6147-6155
38. Willenborg S, Eckes B, Brinckmann J, Krieg T, Waisman A, Hartmann K, Roers A, Eming SA (2014) Genetic ablation of mast cells redefines the role of mast cells in skin wound healing and bleomycin-induced fibrosis. J Invest Dermatol. doi:10.1038/jid.2014.12. 10.1038/jid.2014.12
39. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028-1040
40. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319-12324 (Pubitemid 37271558)
41. Whitfield ML (2014) Editorial: plasma and B cell gene signatures: quantitative targeting and monitoring of B cell-depleting therapies in autoimmune diseases in the genomic era. Arthritis Rheumatol 66:10-14
42. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M et al (2008) CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in amodel of bleomycin-induced scleroderma. AmJ Pathol 172:1650-1663 (Pubitemid 351793356)
43. van Laar JM (2010) B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 12:112
44. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O (2014) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204522
45. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578-583
46. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271-280
47. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res ther 12:R54
48. Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52-57
49. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193-197
50. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii3-7
51. Abraham D (2008) Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology (Oxford) 47(Suppl 5):v8-9
52. Doering K, Rosen A (2012) Autoantibodies in pathogenesis. In: Varga J, Denton CP, Wigley FM (eds) Scleroderma Springer, pp. 199-208
53. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, Buslau M, Worm M, Blank N, Hein R et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13:R172
54. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF (1988) Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 31:378-385 (Pubitemid 18091660)
55. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203 (Pubitemid 18088039)
56. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667-2676
57. Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y, Youinou P (1999) Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 6:156-160 (Pubitemid 29124957)
58. Worda M, Sgonc R, Dietrich H, Niederegger H, Sundick RS, Gershwin ME, Wick G (2003) In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 48:2605-2614 (Pubitemid 37129437)
59. Mihai C, Tervaert JW (2010) Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 69:319-324
60. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, Facchini A, Del Papa N, Borghi MO, Dayer JM et al (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46:1602-1613 (Pubitemid 34620208)
61. Ronda N, Raschi E, Testoni C, Borghi MO, Gatti R, Dayer JM, Orlandini G, Chizzolini C, Meroni PL (2002) Anti-fibroblast antibodies in systemic sclerosis. Isr Med Assoc J 4:858-864 (Pubitemid 35291252)
62. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, Sasaki T, Shoichi O, Takeuchi K, Pandey JP et al (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163:1066-1072 (Pubitemid 29328121)
63. Sato S, Hayakawa I, HasegawaM, Fujimoto M, Takehara K (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120:542-547 (Pubitemid 36343995)
64. Nishijima C, Hayakawa I, Matsushita T, Komura K, Hasegawa M, Takehara K, Sato S (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138:357-363 (Pubitemid 39472456)
65. Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP et al (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60:1137-1144
66. Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145-1151
67. Brinckmann J, Hunzelmann N, El-Hallous E, Krieg T, Sakai LY, Krengel S, Reinhardt DP (2005) Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 7:R1221-1226
68. Ong VH, Denton CP (2012) Investigative approaches to drug therapy. In: Varga J, Denton CP, Wigley FM (eds) Scleroderma. Springer, New York, pp 603-614
69. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62:2787-2795
70. Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16:R53
71. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I et al (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152-157
72. Teng MW, Smyth MJ (2014) Cancer. Can cancer trigger autoimmunity? Science 343:147-148
73. Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Electron microscopy and "in vitro" autoradiography with tritiated thymidine. Arch Dermatol 112:1553-1557
74. Perlish JS, Lemlich G, Fleischmajer R (1988) Identification of collagen fibrils in scleroderma skin. J Invest Dermatol 90:48-54 (Pubitemid 18026954)
75. LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54:880-889
76. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573 (Pubitemid 43139720)
77. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, Huso DL, Dietz HC (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126-130
78. Agarwal P, Schulz JN, Blumbach K, Andreasson K, Heinegard D, Paulsson M, Mauch C, Eming SA, Eckes B, Krieg T (2013) Enhanced deposition of cartilage oligomeric matrix protein is a common feature in fibrotic skin pathologies. Matrix Biol J Int Soc Matrix Biol 32:325-331
79. Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326:1216-1219
80. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmouliere A, Varga J, De Wever O, Mareel M, Gabbiani G (2012) Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 180:1340-1355
81. Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557-567 (Pubitemid 46348510)
82. Hinz B (2010) The myofibroblast: paradigm for a mechanically active cell. J Biomech 43:146-155
83. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3:349-363 (Pubitemid 34619269)
84. Herzog EL, Bucala R (2010) Fibrocytes in health and disease. Exp Hematol 38:548-556
85. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B (2009) The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 86:1111-1118
86. Krieg T, Perlish JS, Fleischmajer R, Braun-Falco O (1985) Collagen synthesis in scleroderma: selection of fibroblast populations during subcultures. Arch Dermatol Res 277:373-376 (Pubitemid 15059779)
87. Jelaska A, Strehlow D, Korn JH (1999) Fibroblast heterogeneity in physiological conditions and fibrotic disease. Springer Semin Immunopathol 21:385-395 (Pubitemid 30433748)
88. Wang Y, Fan PS, Kahaleh B (2006) Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 54:2271-2279 (Pubitemid 44051084)
89. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ, Muller CA, Kalluri R, Zeisberg M (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16:544-550
90. Avouac J, Elhai M, Allanore Y (2013) Experimental models of dermal fibrosis and systemic sclerosis. Joint Bone Spine revue du rhumatisme 80:23-28
91. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110:47-51 (Pubitemid 28086062)
92. Bhattacharyya S, Wei J, Varga J (2012) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42-54
93. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J et al (2012) Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 3:735
94. Beyer C, Distler JH (2013) Morphogen pathways in systemic sclerosis. Curr Rheumatol Rep 15:299
95. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J (2012)Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 64:2734-2745
96. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L et al (2009) WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119:772-787
97. Fleischmajer R, Krieg T, Dziadek M, Altchek D, Timpl R (1984) Ultrastructure and composition of connective tissue in hyalinosis cutis et mucosae skin. J Invest Dermatol 82:252-258 (Pubitemid 14197338)
98. Volloch V, Olsen BR (2013) Why cellular stress suppresses adipogenesis in skeletal tissue, but is ineffective in adipose tissue: control of mesenchymal cell differentiation via integrin binding sites in extracellular matrices. Matrix Biology J Int Soc Matrix Biol 32:365-371
99. Radovanac K, Morgner J, Schulz JN, Blumbach K, Patterson C, Geiger T, Mann M, Krieg T, Eckes B, Fassler R et al (2013) Stabilization of integrin-linked kinase by the Hsp90-CHIP axis impacts cellular force generation, migration and the fibrotic response. EMBO J 32:1409-1424
100. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K (1999) Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112:456-462 (Pubitemid 29171935)
101. Hulmes DJ (2002) Building collagen molecules, fibrils, and suprafibrillar structures. J Struct Biol 137:2-10
102. Myllyharju J, Kivirikko KI (2004) Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 20:33-43 (Pubitemid 38032818)
103. Hynes RO, Naba A (2012) Overview of the matrisome - an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 4:a004903
104. Eckes B, Nischt R, Krieg T (2010) Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair 3:4
105. Franzke CW, Bruckner P, Bruckner-Tuderman L (2005) Collagenous transmembrane proteins: recent insights into biology and pathology. J Biol Chem 280:4005-4008 (Pubitemid 40288560)
106. Kadler KE, Baldock C, Bella J, Boot-Handford RP (2007) Collagens at a glance. J Cell Sci 120:1955-1958 (Pubitemid 47009991)
107. Seth P, Yeowell HN (2010) Fox-2 protein regulates the alternative splicing of scleroderma-associated lysyl hydroxylase 2 messenger RNA. Arthritis Rheum 62:1167-1175
108. Rimar D, Rosner I, Nov Y, Slobodin G, Rozenbaum M, Halasz K, Haj T, Jiries N, Kaly L, Boulman N et al (2013) Lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheum. doi:10.1002/art.38277
109. Brinckmann J, Kim S, Wu J, Reinhardt DP, Batmunkh C, Metzen E, Notbohm H, Bank RA, Krieg T, Hunzelmann N (2005) Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol J Int Soc Matrix Biol 24:459-468 (Pubitemid 41443273)
110. Campbell ID, Humphries MJ (2011) Integrin structure, activation, and interactions. Cold Spring Harbor perspectives in biology 3. DOI 10.1101/cshperspect.a004994
111. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat RevMol Cell Biol 8:221-233
112. DuFort CC, Paszek MJ, Weaver VM (2011) Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol 12:308-319
113. Engler AJ, Sen S, Sweeney HL, DischerDE (2006)Matrix elasticity directs stem cell lineage specification. Cell 126:677-689 (Pubitemid 44233625)
114. Erat MC, Slatter DA, Lowe ED, Millard CJ, Farndale RW, Campbell ID, Vakonakis I (2009) Identification and structural analysis of type I collagen sites in complex with fibronectin fragments. Proc Natl Acad Sci U S A 106:4195-4200
115. Erat MC, Sladek B, Campbell ID, Vakonakis I (2013) Structural analysis of collagen type I interactions with human fibronectin reveals a cooperative bindingmode. J Biol Chem 288:17441-17450
116. Velling T, Risteli J, Wennerberg K, Mosher DF, Johansson S (2002) Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha 11beta 1 and alpha 2beta 1. J Biol Chem 277:37377-37381
117. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG, Markova D, Tsuda T, Timpl R, Chu ML et al (2007) A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 282:11805-11816 (Pubitemid 47100695)
118. Finnis ML, GibsonMA (1997)Microfibril-associated glycoprotein-1 (MAGP-1) binds to the pepsin-resistant domain of the alpha3(VI) chain of type VI collagen. J Biol Chem 272:22817-22823 (Pubitemid 27386102)
119. Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA (1996) A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6:300-313 (Pubitemid 26161692)
120. Gayraud B, Keene DR, Sakai LY, Ramirez F (2000) New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1mutation in the tight skin mouse. J Cell Biol 150:667-680
121. Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, McConnell V, Chillakuri CR, Macaya D, Coucke PJ, De Paepe A, Judge DP, Wigley F, Davis EC, Mardon HJ, Handford P, Keene DR, Sakai LY, Dietz HC (2010)Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med 2: 23ra20. DOI 10.1126/scitranslmed.3000488
122. Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, Jensen S, Zylberberg L, Collod-Beroud G, Bonnet D, Alanay Y et al (2011) Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am J Hum Genet 89:7-14
123. Sengle G, Tsutsui K, Keene DR, Tufa SF, Carlson EJ, Charbonneau NL, Ono RN, Sasaki T, Wirtz MK, Samples JR et al (2012) Microenvironmental regulation by fibrillin-1. PLoS Genet 8:e1002425
124. Kessler D, Dethlefsen S, Haase I, Plomann M, Hirche F, Krieg T, Eckes B (2001) Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J Biol Chem 276:36575-36585
125. Munger JS, Sheppard D (2011) Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biolo 3:a005017
126. Annes JP, Chen Y, Munger JS, Rifkin DB (2004) Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 165:723-734 (Pubitemid 38765773)
127. Sheppard D (2005) Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 24:395-402
128. Wipff PJ, Rifkin DB, Meister JJ, Hinz B (2007) Myofibroblast contraction activates latent TGF-beta1 fromthe extracellularmatrix. J Cell Biol 179:1311-1323 (Pubitemid 350277747)